Epilepsy – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s epilepsy forecast will answer the following questions:
- Of all people diagnosed with epilepsy, how many in the United States, Europe, and Japan are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of epilepsy over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 28 epilepsy patient populations, including the following:
- Diagnosed prevalent cases of epilepsy.
- Diagnosed prevalent cases of epilepsy by type of seizure.
- Diagnosed prevalent cases of epilepsy with status epilepticus.
- Diagnosed prevalent cases of epilepsy by drug-treatment status.
- Drug-treated prevalent cases of epilepsy by drug-resistance status.
- Diagnosed prevalent cases of epilepsy with acute repetitive seizure.
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with intractable epilepsy.
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with sudden tonic or atonic falls.
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with status epilepticus.
- Diagnosed prevalent cases of Dravet syndrome with the SCN1A mutation.
- Diagnosed prevalent cases of Dravet syndrome with status epilepticus.
- Diagnosed prevalent cases of the West syndrome.
- Diagnosed prevalent cases of childhood absence epilepsy.
Note: Coverage may vary by country.
Table of contents
- Epilepsy - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of epilepsy)
- Diagnosed prevalent cases of epilepsy
- Diagnosed prevalent cases of epilepsy by type of seizure
- Diagnosed prevalent cases of epilepsy with status epilepticus
- Diagnosed prevalent cases of drug-resistant epilepsy
- Diagnosed prevalent cases of epilepsy with acute repetitive seizures
- Diagnosed drug-treated prevalent cases of epilepsy
- Diagnosed prevalent cases of Lennox-Gastaut syndrome
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with intractable epilepsy
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with sudden tonic or atonic falls
- Diagnosed prevalent cases of Lennox-Gastaut syndrome with status epilepticus
- Diagnosed prevalent cases of Dravet syndrome
- Diagnosed prevalent cases of Dravet syndrome by severity
- Diagnosed prevalent cases of Dravet syndrome by status epilepticus
- Diagnosed prevalent cases of Dravet syndrome with the SCN1A mutation
- Diagnosed prevalent cases of the West syndrome
- Diagnosed prevalent cases of childhood absence epilepsy
- Risk/protective factors applied to disease forecast models
- Reference Materials
